PDF(Pubmed)
Abstract：
Glioma is the most common malignant tumor in central nervous system, with significant health burdens to patients. Due to the intrinsic characteristics of glioma and the lack of breakthroughs in treatment modalities, the prognosis for most patients remains poor. This results in a heavy psychological and financial load worldwide. In recent years, cannabidiol (CBD) has garnered widespread attention and research due to its anti-tumoral, anti-inflammatory, and neuroprotective properties. This review comprehensively summarizes the preclinical and clinical research on the use of CBD in glioma therapy, as well as the current status of nanomedicine formulations of CBD, and discusses the potential and challenges of CBD in glioma therapy in the future.
摘要：
胶质瘤是中枢神经系统最常见的恶性肿瘤，给患者带来巨大的健康负担。由于神经胶质瘤的内在特征和治疗方式缺乏突破，大多数患者的预后仍然较差。这导致全球范围内沉重的心理和财务负担。近年来,大麻二酚（CBD）由于其抗肿瘤作用而引起了广泛的关注和研究，抗炎,和神经保护特性。本文综述了CBD在脑胶质瘤治疗中的临床前和临床研究。以及CBD纳米药物配方的现状，并讨论了CBD在未来胶质瘤治疗中的潜力和挑战。
